FBT
First Trust NYSE Arca Biotechnology Index ETFNYSEARCA
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Sat, Nov. 12, 4:43 PM
    • Barron's speaks with several prominent money managers.
    • They are hopeful that Donald Trump will enact pro-growth tax and fiscal-stimulus policies, while avoiding overly protectionist measures.
    • Even though biotech stocks have already rallied 10%, fund manager Arun Daniel believes that the benefits of a Trump administration on the bottom lines of biotech and drug companies are not yet fully priced in.  ETFs: IBB, XBI, BIB, BBH, FBT, HQL, PBE, BIS, LABU, BBC, BBP, CNCR, LABD, UBIO, ARKG, ZBIO, LABS
    • He's also bullish on stocks leveraged to government-backed infrastructure spending, his favorites being Jacobs Engineering (NYSE:JEC) and Martin Marietta Materials (NYSE:MLM).
    • Some companies will likely be allowed to repatriate billions of dollars of profits at a low tax rate. Major beneficiaries could include Nike (NYSE:NKE), Procter & Gamble (NYSE:PG), Caterpillar (NYSE:CAT), Visa (NYSE:V) and Mastercard (NYSE:MA).
    • Neuberger Berman's Joseph Amato says that a Trump administration will be better for stocks than bonds. "If [Trump] takes a measured approach and gets some level of concessions for U.S. workers, the trade concerns may be much ado about nothing," Amato says. "But that's a big if."
    | Sat, Nov. 12, 4:43 PM | 211 Comments
  • Tue, Nov. 8, 8:58 PM
    | Tue, Nov. 8, 8:58 PM | 8 Comments
  • Thu, Nov. 3, 2:57 PM
    | Thu, Nov. 3, 2:57 PM | 225 Comments
  • Thu, Apr. 14, 3:58 AM
    | Thu, Apr. 14, 3:58 AM | 7 Comments
  • Oct. 26, 2015, 11:39 AM
    • It's been a "remarkable turn" in relative performance, says Deutsche Bank's David Bianco, noting health care was about 1K basis points ahead of the S&P 500 as recently as mid-August, but both are now about flat and neck-and-neck year-to-date.
      "We find this reversal unwarranted and think health care could surge into year-end," says Bianco, and if the move doesn't come in 2015, it'll surely happen next year. As for valuation, health care is selling for 14.7x 2016E EPS vs. the S&P 500 at 16x - this even as health care's expected 6% sales growth should easily trump that of nominal GDP and the S&P 500. Biano sees 6-9% EPS growth, also better than the S&P.
    • Focus on the big picture, says Bianco: "We believe growth in health care products will stay strong owing to an aging population and increasing efforts to treat conditions with drugs and maximize the productivity of scarce healthcare labor with as many tools and conveniences as conceivable." He likes S&P 500 biotech, pharma, devices, equipment, supplies, tech, and tools, but is cautious on managed care and other healthcare services and facilities.
    • ETFs: IBB, IYH, XLV, XBI, VHT, PJP, BBH, FBT, HQH, CURE, XPH, HQL, PBE, FXH, RXL, IHE, FHLC, SBIO, IHF, PPH, IHI, XHS, RYH, BBC, THQ, PSCH, BBP, XHE, RXD, CNCR, LABD, LABU, UBIO, ZBIO
    | Oct. 26, 2015, 11:39 AM | 18 Comments
  • Oct. 15, 2015, 10:44 AM
    • The first of its kind, the Loncar Cancer Immunotherapy ETF (Pending:CNCR) launches, tracking an index developed by biotech investor Brad Loncar. The expense ratio is 0.79%.
    • Among the names held are Bristol-Myers Squibb, Merck, Juno Therapeutics, and Cellectis. Total holdings number 30.
    • Related ETFs: IBB, XBI, BBH, FBT, HQL, PBE, SBIO, BBC, BBP, LABD, UBIO, LABU, ZBIO
    | Oct. 15, 2015, 10:44 AM | 11 Comments
  • Oct. 13, 2015, 3:49 PM
    • Getting out in front of what should be more bashing of their business models at the Democratic debate tonight, the healthcare names (XLV -1.3%) have about doubled the decline in the S&P 500. Within healthcare, it's the biotechs (IBB -3.1%) and pharmaceuticals (XPH -3.2%) leading the way south.
    • Celgene (CELG -3.3%), Biogen (BIIB -3.6%), Amgen (AMGN -3.5%), Allergan (AGN -4.1%), Mylan (MYL -3.6%)
    • The biotech heavy Russell 2000 (IWM -1.4%) is feeling the pain as well.
    • ETFs: IBB, IYH, XLV, XBI, VHT, PJP, BBH, FBT, HQH, CURE, XPH, HQL, PBE, FXH, RXL, IHE, FHLC, SBIO, PPH, RYH, BBC, THQ, BBP, RXD, LABU, LABD, UBIO, ZBIO
    | Oct. 13, 2015, 3:49 PM | 27 Comments
  • Sep. 27, 2015, 8:59 AM
    • The $8B iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell 4.9% on Friday and 13% for the week - its worst weekly performance since the height of the financial panic seven years ago. Many biotech ETFs eat the same cooking - Gilead (NASDAQ:GILD), Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), and Regeneron (NASDAQ:REGN) among the popular names - and FBT, XBI, and BBP fell in amounts similar to IBB.
    • The news flow was relatively quiet late in the week, but Hilary Clinton's promise Monday to clamp down on drug prices set things in negative motion for the momo sector.
    • Barron's Chris Dieterich reminds that a flood of biotech IPOs in recent years has filled the small cap universe with these highly speculative names, and biotech now makes up 7% of the iShares Russell 2000 Index (NYSEARCA:IWM). Indeed. The IWM fell 3.7% for the week, nearly tripling the decline of the S&P 500.
    • ETFs: IWM, TZA, TNA, UWM, VB, VBK, URTY, SCHA, TWM, IWO, RWM, SRTY, VTWO, RCG, JKJ, VTWG, TWOK, FYX, JKK, EWRS, ZSML, FYC, SMLL, RYRSX
    | Sep. 27, 2015, 8:59 AM | 127 Comments
  • Sep. 25, 2015, 3:07 PM
    | Sep. 25, 2015, 3:07 PM | 134 Comments
  • Sep. 22, 2015, 2:07 AM
    • Democratic presidential candidate Hillary Clinton is scheduled to outline a plan to rein in prescription drug costs in Iowa later today, after vowing on Twitter to go after "price-gouging" by drug companies.
    • The tweet brought down the biotech sector yesterday, with the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) plunging 4.5%.
    • Several details of the new plan have been provided by the Clinton campaign ahead of the speech: A $250 monthly cap on the amount chronic pain patients would have to pay for prescription medications, approving more generic/imported drugs, forcing pharmaceutical companies to reinvest their profits into R&D and ending their ability to write off consumer advertising as a business expense.
    • ETFs: XBI, BIB, BBH, FBT, HQL, PBE, BIS, SBIO, BBC, BBP, UBIO, LABU, LABD, ZBIO
    • Previously: Biotechs take it on the chin after Hillary tweet about plan to address drug price gouging; IBB down 5% (Sep. 21 2015)
    | Sep. 22, 2015, 2:07 AM | 49 Comments
  • Sep. 21, 2015, 12:56 PM
    • The iShares Nasdaq Biotechnology Index Fund (IBB -5%) is down on increased volume, as well as many other ETFs and individual stocks, in apparent response by a tweet by presidential candidate Hillary Clinton stating that price gouging in the specialty drug market is outrageous. Tomorrow, she will "lay out a plan" to take it on.
    • ETFs: IBB, XBI, BBH, FBT, HQL, PBE, SBIO, BBC, BBP, LABD, UBIO, LABU, ZBIO
    | Sep. 21, 2015, 12:56 PM | 83 Comments
  • Jun. 23, 2015, 9:22 AM
    | Jun. 23, 2015, 9:22 AM | 11 Comments
  • May 5, 2015, 4:09 AM
    | May 5, 2015, 4:09 AM
  • Dec. 30, 2014, 1:49 PM
    • In keeping with the trend of biotech focused launches in the last quarter, the ALPS Medical Breakthroughs ETF (Pending:SBIO) will be the last launch of 2014.
    • SBIO is designed to capture research and development opportunities in the biotechnology and pharmaceutical industries through small-cap and mid-cap biotechnology stocks listed in the U.S.
    • Firms with with one or more drugs in Phase II or Phase III FDA clinical trials, with a market cap between $200 million and $5 billion, will be prime candidates for investment.
    • Other domestic biotech ETFs: XBI, BBH, FBT, PBE, BBC, BBP
     
     
    | Dec. 30, 2014, 1:49 PM
  • Dec. 17, 2014, 10:51 AM
    • The BioShares Biotechnology Clinical Trials Fund (NASDAQ:BBC) will track an index of biotechnology companies with a principal focus on running human clinical trials, while the BioShares Biotechnology Products Fund (NASDAQ:BBP) will cover biotechnology companies with one or more drugs approved by the FDA and in commercial production.
    • Both ETFs feature an equal weight index strategy, giving smaller firms a chance to make a meaningful impact on fund movements.
    • “Our BioShares funds are designed with the current biotechnology market in mind and offer investors unique and diversified portfolios of entrepreneurial biotechnology stocks by applying our rules-based index methodology,” said LifeSci Index Partners co-founder, Paul Yook in a statement.
    • Other biotech ETFs: XBI, BBH, FBT, PBE
    | Dec. 17, 2014, 10:51 AM
  • Oct. 31, 2014, 12:47 PM
    • The ARK Genomic Revolution Multi-Sector ETF (NYSEARCA:ARKG) is an actively managed fund that focuses on companies linked to the genomic industry across a number of sectors.
    • The ARK Innovation ETF (NYSEARCA:ARKK) will cover all three investment themes ARK now offers ETF coverage of; industrials through the ARK Industrial Innovation ETF (NYSEARCA:ARKQ), technology through the ARK Web x.0 ETF (NYSEARCA:ARKW) and genomics with ARKG.
    • Other broad technology ETFs: IPK, IXN
    • Other biotech ETFs: XBI, BBH, FBT, PBE
    | Oct. 31, 2014, 12:47 PM
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub